OpEdNews
By K.L. Carlson
August 18, 2010
According to FDA documents, HPV infections do not lead to cervical cancer. “Most infections by HPV are short-lived and not associated with cervical cancer,” states an FDA news release dated March 31, 2003. According to another FDA document, the Gardasil vaccine has been found to increase the risk of developing precancerous lesions by more than 44 percent in young women already infected with the HP virus strains used in the vaccine.
So why are there ads in most women’s and parental magazines stating that HPV causes cervical cancer and the Gardasil vaccine should be given not only to girls as young as nine years old, but also to boys? It’s about money, not health.
Charlotte Haug, MD, PhD, stated her concerns about the Gardasil vaccine in an editorial in the Journal of American Medical Association. “Whether a risk is worth taking depends not only on the absolute risk, but on the relationship between potential risk and the potential benefit”Even if persistently infected with HPV, a woman most likely will not develop cancer if she is regularly screened.”
Gardasil caused 32 deaths and nearly 12,500 serious injuries in the first three years on the market. Ashley Ryburn’s life as a healthy, active teenager changed completely when she was vaccinated with Gardasil. She had to quit all sports activities and cannot even ride her bicycle around the small town where she lives. Ashley’s video story can be seen at http://www.rockymountainnews.com/videos/detail/ashley-story/.
Physician Scott Ratner’s daughter became seriously ill with a chronic immune disease after her first dose of Gardasil. Dr. Ratner told CBS News, “She would have been better off getting cervical cancer than the vaccine.”
If the 44.6% number represented what the FDA concluded and then went ahead and licensed the HPV vaccine, they would be insane.
They are not insane. The number originated in a table on page 13 of this document: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf . The FDA in text and tables on pages 13, 14 and 15 provide more details.
On page 15, the FDA concluded:
”
Therefore, while the subgroup from study 013 remains a concern of the clinical review team, there is some evidence that this represented an unbalanced subgroup where Gardasil™ recipients at baseline had more risk factors for development of CIN 2/3 or worse. Furthermore, when the subgroups from three studies are combined, these groups appear to be more similar. Finally, there is compelling evidence that the vaccine lacks
therapeutic efficacy among women who have had prior exposure to HPV and have not cleared previous infection (PCR positive and seropositive), which represented approximately 6% of the overall study populations.”
By the way, the product insert for Gardasil shows that more test subjects died after receiving the placebo than died after getting the vaccine. What does this mean? Nothing, the numbers were pretty close and not out of line of what was expected.
First, in real life, no one with ‘other risk factors’ is being eliminated from HPV vaccination. Therefore, trial number 013 is probably a pretty accurate indication of the results of HPV vaccinations in the real world. The subgroup from study 013 should, indeed remain a concern.
Second, you do not mention that the so-called “placebo” group was injected with Merck’s proprietary adjuvant–that has not been tested for safety and/or efficacy–not exactly a ‘placebo’ in any sense of the word.
In any scientific circle in the world, there was no ‘placebo’ used in the clinical trials for Gardasil.